ARDS is a heterogeneous syndrome, and macrophage responses are niche depended on, thus, further studies are warranted to establish whether CB2 agonists signaling are broadly effective or it is a more selective intervention. The gene discussed is CNR2; the disease is acute respiratory distress syndrome.